|
|
|
|
|
Pegvisomant
drug data and news
Pegvisomant drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Pegvisomant | ||
| Brand Names/Synonyms | Somatotropin precursor;Growth hormone;GH;GH-N;Pituitary growth hormone;Growth hormone 1; Somavert (Pfizer Inc) | ||
| Indication | For treatment of acromegaly | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Somavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly. | ||
| Mechanism Of Action | Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels. | ||
| Pegvisomant News (When available) |
| ||
| Dosage Forms | Not Available | ||
| Drug_Category | Anabolic Agents; Hormone replacement | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | PEGylated human growth hormone | ||
| Chemical Formula | C990H1532N262O300S7 | ||
| Molecular Weight | 22129 | ||
| Smiles String | Not Available | ||
| Melting Point | 76 oC at pH 3.5 (Gomez-Orellana, I. et al., Protein Sci. 7:1352-1358 (1998). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.411 | ||
| Isoelectric Point | 5.27 | ||
| Biotransformation | Not Available | ||
| Half Life | ~6 days | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Pegvisomant.html http://www.rxlist.com/cgi/generic3/somavert.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00044 | ||
| CAS Registry Number | Not Available | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10154 | ||
| SwissProt ID | SOMA_PANTR (P58756) | ||
| GenBank ID | AF374232 | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |